Загрузка...
Overcoming Resistance to Antiangiogenic Therapies
The concept of targeting new blood vessel formation, or angiogenesis, in tumors is an important advancement in cancer therapy, resulting, in part, from the development of such biologic agents as bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF)-A. The rati...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AlphaMed Press
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3425522/ https://ncbi.nlm.nih.gov/pubmed/22773560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0068 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|